Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Ascierto, Paolo A., Puzanov, Igor, Agarwala, Sanjiv S., Blank, Christian, Carvajal, Richard D., Demaria, Sandra, Dummer, Reinhard, Ernstoff, Marc, Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Lo, Roger S., Long, Georgina V., Luke, Jason J., Osman, Iman, Postow, Michael A., Sullivan, Ryan J., Taube, Janis M., Trinchieri, Giorgio, Zarour, Hassane M., Caracò, Corrado, Thurin, Magdalena
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Meeting Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487701/
https://ncbi.nlm.nih.gov/pubmed/32894202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02482-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados